1717 K Street NW, Suite 900

Washington, DC 20006-5349

(877) 363-6376

HELPLINE

NEWS

Important Study

Researcher

For many reasons cancer patients do not always wish to participate in a clinical trial or are not eligible for trials. I would like all of the patients who are on our site to consider participating in Dr Jill Ohar’s study. It does not involve treatment or travel but does require that you fill out a questionnaire provide saliva for DNA and hopefully add to the scientific inquiry as to what are the Phenotypic and Genotypic Determinants to Identify Patients at High Risk for Mesothelioma. Your data and samples provided are kept confidential and identifiers are coded to protect your privacy. This study has been approved by the Wake Forest IRB and is being conducted under their strict ethical guidelines. Please take a minute to read by following this link https://www.curemeso.org/site/c.kkLUJ7MPKtH/b.5422319/k.693C/Participate_in_Study.htm . Adding to the scientific body of knowledge will one day result in more effective screening, effective treatment strategies and hopefully a cure. In a study funded by the Mesothelioma Foundation Dr Ohar has identified an alarming rate of cancers in family members of patients with mesothelioma. You can read more about her research by following the quick link. Take a moment and help all members of the mesothelioma community and many more who have been exposed to asbestos and have yet to be diagnosed. This is a rare opportunity that can have a huge impact and requires so little effort on your part. Please join us in the fight and make a difference.

~Mary Hesdorffer, NP

Click here to contact Mary Hesdorffer, Nurse Practitioner or call 877.363.6376
Also...

In Other News

Clinical Trials

Mesothelioma is one of the rarest cancers so there are always clinical trials going on to advance research efforts. This session presents on four different

Read More »

Peritoneal Surgery/HIPEC

Peritoneal mesothelioma patients have a few different treatment options available. This session discusses two options: surgery as well as hyperthermic intraperitoneal chemotherapy (HIPEC).  This session

Read More »

Share:

Facebook
Twitter
LinkedIn